Figma Inc. Class A Common Stock vs Natera Inc. Common Stock — how do they compare? Figma Inc. Class A Common Stock trades at $21.24 (market cap $11.60B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.9× Figma Inc. Class A Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Natera Inc. Common Stock for 0 Days on average.
| FIG | NTRA | |
|---|---|---|
Market Cap | $11.60B | $57.03B |
Volume | 12,281,013 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $63.82 | $425.64 |
52-Week Low | $16.84 | $179.42 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.00B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →